Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Mitoxantrone Liposome + CNOP in DLBCL
NCT02595242Phase 1Withdrawn
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Jun 2015; status: withdrawn.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02595242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595242.